A phase 2a proof of concept clinical trial to evaluate ZPL-3893787 (ZPL-389) a potent, oral histamine H4, receptor antagonist for the treatment of moderate to severe atopic dermatitis (AD) in adults
Werfel, T.; Lynch, V.; Asher, A.et al.
2016 • In Journal der Deutschen Dermatologischen Gesellschaft
adult adverse; drug reaction; antiinflammatory activity; atopic dermatitis; body surface; clinical trial; controlled clinical trial; controlled study; cornea ulcer; double blind procedure; efficacy parameters; female human major clinical study; male parallel design phase 2 clinical trial; pruritus randomized controlled trial side effect; visually impaired person; endogenous compound; histamine H4 receptor; antagonist placebo
Abstract :
[en] It is well documented that histamine-induced inflammation is largely mediated through the H4 receptor (H4R). T lymphocytes and keratinocytes from patients with atopic dermatitis (AD) express high levels of H4R which mediate cytokine upregulation and histamine-induced proliferation. The identification of IL-17 positive cells in psoriatic lesions, and the fact that these cells expressed a functional H4R, lends weight to its therapeutic potential in inflammatory skin diseases such as AD and psoriasis. ZPL-389 is a low nanomolar and selective H4R antagonist.
Disciplines :
Dermatology
Author, co-author :
Werfel, T.; Hannover Medical University, Germany > Departement of Dermatology
Lynch, V.; MAC Clinical Research Ltd, Monarch House, Stourton, Leeds, United Kingdom
Asher, A.; MAC Clinical Research Ltd, CityLabs, Manchester
Tsianakas, A.; Universität Münster, Klinik für Hautkrankheiten, Germany > Dermatologie und Venerologie
Gupta, B.; MAC Clinical Research Ltd, Faraday Way, Blackpool, United Kingdom
Sarmiento, R.
Ploszczuk, A.
Majorek-Olechowska, B.
Cimoszko, B.
NIKKELS, Arjen ; Centre Hospitalier Universitaire de Liège - CHU > Autres Services Médicaux > Service de dermatologie
A phase 2a proof of concept clinical trial to evaluate ZPL-3893787 (ZPL-389) a potent, oral histamine H4, receptor antagonist for the treatment of moderate to severe atopic dermatitis (AD) in adults
Publication date :
2016
Journal title :
Journal der Deutschen Dermatologischen Gesellschaft
